Smith & Nephew Earnings Call Highlights Profitable Momentum
Smith & Nephew Snats ((SNN)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Smith & Nephew’s latest earnings call struck a distinctly upbeat tone, with management highlighting strong execution, clear momentum in margins and cash generation, and broad-based growth across business units. While they acknowledged tangible but manageable headwinds in China, U.S. reimbursement and tariffs, the overall message was that structural improvements and innovation are overpowering these pressures.
Revenue Growth Accelerates Through FY2025
Smith & Nephew delivered FY2025 revenue of $6.2 billion, up 5.3% on an underlying basis and 6.1% reported, modestly ahead of guidance and confirming a solid growth trajectory. Over 2022–2025, revenue compounded at 5.7%, underscoring a consistent expansion story rather than a one-off rebound.
Strong Q4 Caps the Year With Broad-Based Momentum
The year closed on a high note as Q4 revenue reached $1.7 billion, up 6.2% underlying and 8.3% reported, boosted by a 210-basis-point currency tailwind. Average daily sales advanced 4.5%, with growth well spread across regions, including 5.6% in the U.S., 7.2% in other established markets and 6.4% in emerging markets.
Margin Expansion Drives Trading Profit Higher
Profitability stepped up meaningfully, with trading profit rising to $1.2 billion, an increase of $162 million year on year. Trading margin expanded by 160 basis points to 19.7%, helped by a 60-basis-point improvement in gross margin to 70.9%, signaling better pricing, mix and cost control.
Cash Generation Strengthens Balance Sheet and Returns
Free cash flow surged 52.5% to $840 million, significantly ahead of initial expectations and providing ample financial flexibility. Net debt stood at $2.76 billion, or around 1.7 times adjusted EBITDA, while return on invested capital improved to 8.3%, and nearly 10% when stripping out portfolio rationalization effects.
Cost Savings and Operational Discipline Take Hold
Management reported cumulative efficiency savings of $280 million by the end of 2025 against a 2027 target of $325–375 million, confirming tangible progress. These enterprise-wide initiatives, alongside manufacturing optimization and productivity gains, underpinned the 160-basis-point margin expansion and contributed to a sharp reduction in days sales inventory.
Innovation Engine Fuels Growth and Robotics Adoption
Innovation is increasingly central to growth, with over 60% of 2025 expansion coming from products launched in the last five years and 44 launches over the past three. The company plans 16 more launches in 2026 and highlighted record CORI robotics placements, with 45% going into ambulatory surgery centers and CORI-linked accounts seeing knee growth roughly 850 basis points higher.
Capital Allocation, Buybacks and Portfolio Moves
Smith & Nephew completed a $500 million share buyback in the second half, supporting a 21% rise in adjusted EPS to $1.02 and proposing a 4.3% dividend increase to $0.391. On the strategic side, the announced purchase of Integrity Orthopaedics, for up to $450 million, is intended to strengthen its shoulder and rotator cuff offering and deepen the portfolio.
China VBP Remains a Drag but Is Stabilizing
China’s Value-Based Procurement program weighed on 2025, shaving around 170 basis points from group growth and cutting Greater China sales by roughly one-third to about $160 million. Looking ahead, management expects China to be broadly neutral for the top line in 2026, though profits should still fall by $15–20 million due to further procurement pressure in selected categories.
U.S. Reimbursement Changes Hit Skin Substitutes
The company flagged meaningful pressure from changes to reimbursement and pricing caps on its skin-substitute products in physician-office and mobile settings. These rules are expected to force price reductions of about 20–25%, translating into a 15–20% revenue decline in that subsegment and a potential $20–40 million hit to trading profit next year.
Wound Care and Bioactives Show Pockets of Softness
Not all areas are firing, with Bioactives dipping 0.5% in Q4 as it cycled a strong launch and faced channel slowdown, illustrating the sensitivity of this niche. Advanced Wound Management grew just 2.8% in the quarter, and while advanced wound care rose 4.4%, it signaled that some wound categories are growing below group averages.
One-Off Portfolio Rationalization Weighs on Reported Profit
To clean up its range and simplify operations, Smith & Nephew booked a $159 million charge tied to inventory and portfolio rationalization, including cutting about two-thirds of orthopaedic SKUs and around 10% in Sports Medicine. Management stressed this is a one-time hit that temporarily depresses reported profit but should support better asset efficiency and margins in future years.
Managing U.S. Knee Volatility and LANDMARK Rollout
U.S. Knee performance has been uneven, despite recent improvement, and management cautioned on a softer first quarter of 2026 as it balances growth, profitability and asset efficiency. Investments in the LANDMARK knee launch and commercialization are being phased with an eye toward achieving at least market-level growth by the fourth quarter.
Extraordinary 2026 Headwinds to Profitability
The company outlined several exceptional pressures on 2026 profits, including a sharp rise in tariffs to about $60 million from $17 million and the wound reimbursement changes. Additional impacts from inventory revaluation and procurement in China, plus the Integrity deal being marginally dilutive initially, will all weigh on earnings but are expected to be offset over time by savings and operational leverage.
Temporarily Lower Cash Flow Guidance and Higher Restructuring
Despite a strong 2025 cash performance, free cash flow is expected to slip slightly to around $800 million in 2026 as restructuring costs edge up. These expenses relate mainly to manufacturing network optimization, including site closures and transitions, which are intended to unlock further efficiency gains and margin benefits beyond the coming year.
Guidance and Medium-Term Ambitions Point to Further Upside
For 2026, management guided to about 6% organic revenue growth and roughly 8% organic trading profit growth, implying continued margin expansion and around $1.3 billion of trading profit. They see free cash flow near $800 million, return on capital above 10% excluding the new deal and reiterated mid-term goals of 6–7% revenue growth, 9–10% profit growth, more than $1 billion free cash flow and double-digit ROIC by 2028.
Smith & Nephew’s earnings call painted the picture of a company in control of its own improvement story, using cost discipline, portfolio pruning and innovation to push margins and cash higher. While investors must factor in 2026 headwinds from China, reimbursement and tariffs, the medium-term roadmap and robust balance sheet provide a strong underpinning for the ongoing earnings recovery.
